Serum phenytoin levels with different brands.

Area of Science:

• Pharmacology
• Clinical Neurology

Background:

• Phenytoin is a key antiepileptic drug.
• Ensuring therapeutic equivalence across different brands is crucial for patient care.

Purpose of the Study:

• To compare the therapeutic efficacy of four different brands of phenytoin.
• To assess serum phenytoin levels and seizure control in newly diagnosed epileptic patients.

Main Methods:

• A randomized study involving 60 newly diagnosed epileptic patients.
• Patients were equally divided into four groups, each receiving a different phenytoin brand.
• Serum phenytoin levels were measured using EMIT and spectrophotometric methods.
• Seizure control and remission rates were monitored.

Main Results:

• All four phenytoin brands demonstrated equivalent therapeutic efficacy.
• Serum phenytoin levels showed good correlation between EMIT and spectrophotometric methods (r=0.985).
• Higher serum phenytoin levels (over 5 µg/ml) were associated with better seizure control.
• Serum phenytoin levels at two weeks were significantly higher than at three months in most patients.

Conclusions:

• The four studied phenytoin brands are therapeutically equivalent for epilepsy management.
• Monitoring serum phenytoin levels is important for optimizing seizure control.
• Brand-to-brand consistency in phenytoin therapy is supported by these findings.